Slides and webcasts from ESMO Virtual Plenaries are open to all, ESMO Members and free ESMO Account holders, according to the presenters' agreement to release them.
Login and Watch now!
Randomised Phase III Trial Data on the Efficacy and Safety of Cemiplimab as Opposed to Chemotherapy in Patients with Progressive Advanced Cervical Cancer
- Start date
- 12 May 2021
- End date
- 13 May 2021
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
Programme
Wednesday, 12 May 2021
19:30-20:30 CEST
Welcome and introduction, Scientific background and context
Susana Banerjee, Royal Marsden Hospital, London, UK
EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
Krishnansu S. Tewari, University of California Irvine, Orange, CA, USA
Critical analysis and perspectives
Mansoor Mirza, Rigshospitalet, Copenhagen, Denmark
Discussion and Q&A (i)
Faculty and online audience
Thursday, 13 May 2021
13:15-14:15 CEST (19:15 HKT / 20:15 JST / 21:15 AEST)
Webcast of 12 May presentations, Discussion and Q&A (ii)
Faculty and online audience:
Keiichi Fujiwara, Saitama Medical University International Medical Center, Saitama, Japan
Krishnansu S. Tewari, University of California Irvine, Orange, CA, USA
Hextan Yuen-Sheung Ngan, University of Hong Kong, Hong Kong, China
David Tan, NUHS - National University Health System, Singapore
